Abstract Dilated cardiomyopathy (DCM) is a common cause of heart failure, and identification of early pathogenic events occurring prior to the onset of cardiac dysfunction is of mechanistic, diagnostic, and therapeutic importance. The work characterized early biochemical pathogenesis in TO2 strain hamsters lacking d-sarcoglycan. Although the TO2 hamster heart exhibits normal function at 1 month of age (presymptomatic stage), elevated levels of myeloperoxidase, monocyte chemotactic protein-1, malondialdehyde, osteopontin, and alkaline phosphatase were evident, indicating the presence of inflammation, oxidative stress, and osteogenic phenotype. These changes were localized primarily to the myocardium. Derangement in energy metabolism was identified at the symptomatic stage (4 month), and is marked by attenuated activity and expression of pyruvate dehydrogenase E1 subunit, which catalyzes the rate-limiting step in aerobic glucose metabolism. Thus, this study illustrates differential involvement of oxidative stress, osteogenic phenotype, and glucose metabolism in the initiation and early progression of d-sarcoglycan-null DCM.
Introduction
Dilated cardiomyopathy (DCM) is a common cause of heart failure, and is the most prevalent cardiomyopathy [1] . DCM can result from myocardial infarction, myocarditis, mitochondrial dysfunction, and genetic abnormalities, representing the end result of diverse pathways [2, 3] . The complex nature of DCM can be attributed in part to progressive tissue remodeling at the cellular and molecular levels of the affected heart [4, 5] . While much progress has been made in the understanding of molecular genetics of DCM in the past decade, it remains incompletely elucidated how alterations occurring at the molecular level mediate the development of the disease, which often occurs in the setting of autoimmune cardio-inflammatory processes [6] [7] [8] .
Identified DCM genes encode cytoskeletal, sarcomeric, mitochondrial, and membrane proteins [6] . Alterations of these proteins are thought to impact mechanical force generation/transmission, signal transduction, energy metabolism, and sarcolemmal stability [9] . For instance, mutations of the muscle-specific intermediate filament protein desmin can cause DCM exhibiting myocardial degeneration, calcium overload, and compromised respiratory chain [10, 11] . Sarcomeric protein mutations can indirectly derange the energy status through inefficient myocardial energy use [12, 13] . Altered energy metabolism may have a substantial role in the development of DCM since specific mutations in mitochondrial DNA have been found in DCM patients that compromise energy production [14, 15] . Oxidative stress represents yet another aspect of the multi-faceted pathologic process that can be triggered by mitochondrial dysfunction and inflammatory response [7, 8, 16] . Although these diverse, but interrelated mechanisms are expected to act in a chronological cascade, early pathogenic events that occur prior to the manifestation of cardiac dysfunction are particularly important since these pathways can be of diagnostic and therapeutic values.
The TO2 hamster model of DCM, which is associated with d-sarcoglycan mutation, exhibits cardiac dysfunction between 1 and 2 months of age, and later develops congestive heart failure resembling that seen in many patients [17] [18] [19] [20] . Mouse models of d-sarcoglycan deficiency have been created and shown to cause sarcolemmal fragility culminating in DCM [21, 22] . Mutation of the human dsarcoglycan gene causes familial and idiopathic DCM associated with limb-girdle muscular dystrophy [23, 24] . Since the hamster DCM model displays successive and uniform phases of pathophysiologic changes, it was used here to identify early biochemical and molecular alterations involved in the initiation and progression of DCM.
Materials and methods

Animals
Bio-F1B (normal control) and Bio-TO2 (DCM) male hamsters were obtained from Bio Breeders (Watertown, MA, USA). Procedures and protocols conformed to institutional guidelines for the care and use of animals in research. The number of animals used for each experiment is indicated in the figure legends.
Transthoracic echocardiography
Animals were anesthetized by intraperitoneal (ip) injection of xylazine (2 mg/kg) and ketamine (25 mg/kg), and remained semi-conscious during the measurement procedure. Multiple M-mode images were obtained from the short axis view of the left ventricle at the level of the papillary muscles with a GE Vingmed echo machine using a 10-MHz transducer. From this image, left ventricular end-systolic dimension (LVDs) and left ventricular enddiastolic dimension (LVDd) were measured. These dimensions were measured and averaged from at least two consecutive cardiac cycles.
Tissue lysate preparation Animals received 1,000 units of heparin by i.p. injection prior to sacrifice by CO 2 narcosis. Tissues were immediately excised and rinsed in ice-cold Hank's Balanced Salt Solution several times. Blood samples (0.5 ml per animal) were immediately collected after the heart was excised. Plasma fractions were recovered after brief centrifugation. Freshly isolated tissue samples were minced and homogenized in an ice-cold lysis solution (phosphate-buffered saline supplemented with 0.1% Triton X-100). Homogenates were clarified by a 2-min spin in a refrigerated microfuge. Supernatants and pelleted membrane fractions were separated, following which the membrane fractions were resuspended in the lysis solution, and used for pyruvate dehydrogenase (PDH) and cytochrome c oxidase (COX) assays. Supernatants were used for lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) assays. Protein concentrations were determined using the BCA protein assay method (Pierce, Rockford, IL, USA). Samples were frozen in small aliquots at -80°C.
Enzyme assays
LDH activities were determined as described in our previous study [25] . Assays were initiated by mixing 5 ll of tissue samples with 50 ll of the LDH substrate solution in a 96-well plate. The plate was incubated at 37°C for 30 min, following which LDH activities were measured by absorption at 492 nm. For ALP assay, samples (10 ll) were mixed with 0.1 ml of an ALP substrate solution (100 mM Tris pH 10.5, 2 mM MgCl 2 , and 2.5 mM p-nitrophenyl phosphate) in a 96-well plate, and incubated at 37°C for 30 min. Reactions were stopped by 20 ll 1 N NaOH and measured by absorption at 412 nm. Tissue ALP activities were expressed as optical density units (412 nm) per mg proteins. The PDH and GAPDH assay kits, which is based on a coupled PDH/GAPDH and diaphorase reaction converting the chromogenic substrate p-iodonitrotetrazolium violet (INT) to formazan, was from Biomedical Research Service (Buffalo, NY, USA). COX activity was measured using an assay kit from Sigma (Saint Louis, MO, USA), which is based on observation of the decrease in absorbance at 550 nm of ferrocytochrome c caused by its oxidation to ferricytochrome c by cytochrome c oxidase.
MDA assay
The malondialdehyde (MDA) kit was purchased from Biomedical Research Service (Buffalo, NY, USA). For lipid peroxidation assays, 0.1 ml of TCA-treated plasma and tissue homogenates were incubated with freshly prepared 6.5 mg/ml thiobarbituric acid at 95°C for 30 min. Reaction products were extracted with n-butanol and measured at 540 nm. MDA concentrations were calculated using a molar extinction coefficient of 1.56 9 10 5 cm
Glucose measurement
Plasma glucose was measured using the One Touch blood glucose monitoring system (Johnson&Johnson, Milpitas, CA, USA).
Multiplexed immunoassays of plasma samples
Hamster plasma samples were analyzed by Rules-Based Medicine, Inc. (Austin, TX, USA) using their rodent MAP analysis program. Plasma levels of myeloperoxidase, monocyte chemotactic protein-1, SGOT, insulin, osteopontin, and leptin were obtained using the MAP analysis.
Western blotting
Total proteins were resolved by SDS-PAGE and electrotransferred to Immobilon-P membrane as described [26] .
The membrane was incubated with a 1,000-fold diluted primary antibody solution followed by washing with a saline solution supplemented with 0.025% TW-20. Secondary antibodies were conjugated with horse radish peroxidase. Protein bands were visualized using the chemiluminescent substrate system (Pierce, Rockford, IL, USA) and imaged by Fuji imager. The PDH-E1a antibody (#A-21323) and the 39-kDa subunit of Complex I antibody (#A-21344) were purchased from Molecular Probes (Eugene, OR, USA).
Statistics
Data presented were representatives of at least two separate assays, and were means ± SEM. Some error bars were too small to appear on the graph. Student's t-tests were used for statistical analysis.
Results
Presymptomatic and symptomatic stages of hamster DCM
Identification of early pathologic events that occur prior to the manifestation of cardiac dysfunction is of mechanistic, diagnostic, and therapeutic importance. We carried out physiological and biochemical analyses focusing on the initiation and progression of the TO2 DCM. We first used echocardiography to define the presymptomatic and symptomatic phases. Figure 1a illustrates left ventricular ejection fraction (LVEF) and diastolic diameter (LVDd) of F1B (normal control) and TO2 (DCM) hamsters at 1, 4, and 8 months of age, showing that the TO2 hamster heart at 1 month is functionally normal, in agreement with previous studies [18, 27] . LVEF and LVDd of TO2 hamsters deteriorated by approximately 25 and 5% at 4 months, respectively, and continued to deteriorate with aging. We further examined circulating biomarkers for signs of tissue damage. As shown in Fig. 1b , the 1-month TO2 hamsters exhibited normal circulating levels of serum glutamic oxaloacetic transaminase (SGOT) and lactate dehydrogenase (LDH). Consistent with the echocardiographic analysis, the 4-month TO2 hamsters exhibited elevated levels of SGOT and LDH, indicating signs of tissue damage (Fig. 1b) . These results are in agreement with published histological findings [27] . We thus refer the 1-and 4-month stages as the presymptomatic and symptomatic phases of hamster DCM.
Oxidative stress at the presymptomatic stage
Although the 1-month TO2 hamster heart appeared largely normal, early subtle biochemical pathogenesis might be occurring that was not revealed by the above analyses. Plasma samples from 1-month F1B and TO2 hamsters were therefore screened by multiplexed immunoassays examining *70 circulating biomarkers, among which the neutrophil enzyme myeloperoxidase and the inflammatory cytokine monocyte chemotactic protein-1 were significantly elevated in the asymptomatic TO2 hamsters (data (expressed as relative O.D. units) and SGOT levels (expressed as lg/ ml). Each time point was from n = 3. Results were means ± SEM. P values shown were comparisons between F1B and TO2 hamsters as indicated not shown). Since activities of these two proteins can cause oxidative stress [28] , we measured plasma concentrations of malondialdehyde (MDA), which represents the endproduct of lipid peroxidation [29] . Figure 2a shows that circulating MDA levels increased with age (from 1 to 4 months) in both F1B and TO2 hamsters. Notably, TO2 hamsters exhibited significantly higher plasma MDA levels than F1B hamsters at 1 month only. Analysis of tissue MDA reveals that heart tissues from both strains at 1 month of age accumulated higher levels of MDA than skeletal muscle and liver tissues (Fig. 2b) . These biochemical assays thus uncover early oxidative stress predominantly affecting the TO2 heart at the presymptomatic stage.
DCM heart expresses osteogenic markers at the presymptomatic stage
Oxidative stress-induced molecular signaling has recently been shown to activate osteogenic differentiation of vascular smooth muscle cells [30] . Circulating osteopontin and alkaline phosphatase (ALP) are sensitive osteogenic markers that are of diagnostic value [30, 31] . Figure 3a shows that plasma osteopontin levels and ALP activities were significantly higher in both 1-and 4-month TO2 hamsters, suggesting ongoing abnormal osteogenic events. Heart ALP activities were further analyzed, and found to be significantly higher in both 1-and 4-month TO2 hearts (Fig. 3b) . These analyses indicate early aberrant activation of an osteogenic pathway in the TO2 heart before the onset of cardiac dysfunction, and the abnormal osteogenic phenotype persisted after the manifestation of DCM.
TO2 hamsters exhibit an abnormal hormonal profile
The UM-X7.1 cardiomyopathic hamster strain has previously been found to exhibit insulin deficiency and reduced expression of lipogenic enzymes [32] . Since altered energy metabolism may have a substantial role in the development of DCM [14, 15] , we next investigated whether regulation of energy metabolism in the TO2 cardiomyopathic hamster strain might be altered. Insulin and leptin are two key hormones involved in regulation of whole body metabolism. Interestingly, immunoassays revealed abnormally low levels of plasma insulin and leptin in 1-month TO2 hamsters (Fig. 4a) . The observed insulin abnormality appeared transient as it became normalized at 4 months of age. The leptin abnormality on the other hand persisted from 1 to 4 months of age (Fig. 4a) . Despite the transient insulin abnormality, the TO2 hamsters exhibited normal blood glucose levels at both 1 and 4 months of age (Fig. 4b ).
Selective downregulation of aerobic glucose metabolism at the symptomatic stage
Early insulin abnormality at the presymptomatic stage can potentially have a long-term effect on energy metabolism, leading to subsequent left ventricular pump failure. Pyruvate dehydrogenase (PDH) complex catalyzes the rate-limiting step in aerobic glucose metabolism, and the E1 subunit of the Fig. 2 TO2 hamster DCM exhibits presymptomatic oxidative stress. MDA assays were performed as described [25] using plasma (a) and tissue homogenates (b) from 1-month hamsters (n = 3 for each bar). MDA concentrations (lM) shown were means ± SEM. P values shown were comparisons between F1B and TO2 as indicated enzyme complex is normally activated by insulin [33, 34] . We carried out enzyme activity assays examining ventricular PDH activities at 1 and 4 months. Figure 5a shows that F1B and TO2 ventricular homogenates exhibited similar PDH activities at the presymptomatic stage (1 month). Interestingly, a prominent age-dependent increase in PDH activities was noted in the F1B but not TO2 samples, resulting in a *40% lower TO2 PDH activities at the symptomatic stage (4 month). Decreased PDH activities were not observed in the TO2 muscle and liver samples (data not shown). We also assayed two additional enzymes involved in energy metabolism. Figure 5b shows that F1B and TO2 hearts exhibited similar activities of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cytochrome c oxidase (COX) activities from 1 to 4 months, indicating that the observed downregulation of PDH activity in the heart of 4-month TO2 hamsters is mechanistically unique and significant.
Downregulated expression of PDH E1 subunit at the symptomatic stage
Since the E1 subunit of PDH catalyzes the rate-limiting step, and its expression is regulated by insulin [33, 34] , we examined the amount of the E1 subunit by Western blotting. Figure 6a shows that ventricular tissues from 1-month F1B and TO2 hamsters contained similar amount of E1 protein, which is consistent with the enzyme activity assay shown in Fig. 5 . Ventricular tissues from 4-month F1B hamsters exhibited significantly higher levels of E1 protein than those from 4-month TO2 hamsters, which again is consistent with the enzyme activity assay. Expression of the 39-kD subunit of the electron transport chain complex I was also examined as internal reference, and found to be similar in F1B and TO2 samples (Fig. 6a) . Densitometric quantification of the Western blots revealed a *20% decrease in PDH E1 protein in the ventricles of 4-month TO2 hamsters (Fig. 6b) . Thus, lower PDH activities in the 4-month TO2 myocardium are caused at least in part by downregulated expression of the PDH E1 subunit.
Discussion
The present study was undertaken to identify early biochemical pathogenesis in the TO2 hamster model of DCM, which exhibits cardiac dysfunction between 1 and Fig. 4 Abnormal regulation of insulin and leptin in TO2 hamsters.
(a) Plasma levels of insulin (uIU/ml) and leptin (ng/ml) were determined by the MAP analysis. (b) Plasma glucose concentrations (mg/dL) were determined using the OneTouch glucose strips. All data were from n = 3. Data shown were means ± SEM. P values shown were comparisons between F1B and TO2 hamsters as indicated Fig. 5 The symptomatic stage of TO2 DCM is associated with downregulation of heart pyruvate dehydrogenase (PDH) activity. Tissue homogenates were prepared from ventricular tissue at 1 and 4 months (n = 3 for each time point). Pelleted membrane fractions were used for PDH assay (a) and COX assay (b). Soluble fractions were used for LDH assay (b) PDH and LDH enzyme activities (expressed as O.D. units per mg proteins) were normalized by total protein concentrations. COX enzyme activities were expressed as units/ml. Results were means ± SEM. P values were comparison between F1B and TO2 at the time point indicated. Muscle and liver PDH activities were also measured, and were found to be similar between F1B and TO2 hamsters (data not shown) were analyzed by SDS-PAGE followed by Western blotting using antibodies specific for PDH E1 subunit and the 39-kD subunit of the electron transport chain complex I. (b) Relative abundance of each detected protein band was quantified by densitometric analysis, and illustrated in arbitrary densitometric units. The P value shown was comparison between F1B and TO2 at the time point indicated 2 months of age and later develops congestive heart failure resembling that seen in many patients [35, 36] . We found that oxidative stress, osteogenic phenotype, and energy metabolism are differentially involved in the initiation and progression of the disease. Although TO2 hamsters at 1 month of age are functionally normal and exhibit little histological abnormalities, signaling pathways may be altered at the early presymptomatic stage that are likely to be mechanistically and clinically significant. d-Sarcoglycan is a component of the multifunctional dystrophin-associated glycoprotein complex, which provides mechanical strength and mediates signal transduction in the cell [19, 21, 37] . Since loss of d-sarcoglycan protein destabilizes the dystrophin complex, the signaling linkage between the cytoskeletal network and extracellular matrix is expected to be altered in d-sarcoglycan-deficient tissue. d-Sarcoglycan has been shown to interact physically with the b1-integrin signaling molecule and mediate cell adhesion [38, 39] . Along this line, we note that metabolic and signaling abnormalities have been demonstrated in the dystrophin-deficient mouse heart prior to the onset of overt cardiomyopathy [40] . These molecular events may be mediated by lipid peroxidation as evidenced here by increased concentrations of MDA, myeloperoxidase, and monocyte chemotactic protein-1 in 1-month TO2 hamsters. Myeloperoxidase, in particular, has been linked to the production of prothrombogenic oxidized lipids [41] , and high levels of myeloperoxidase are detected in patients with angiographically documented cardiovascular disease and culprit lesions prone to rupture [42, 43] .
Oxidative stress-induced signaling has recently been shown to activate osteogenic differentiation of vascular smooth muscle cells [30] . A commonly used osteogenic marker is the phosphate-splitting enzyme alkaline phosphatase (ALP), which is induced during the early stage of osteogenesis [30, 31] . Although aberrant circulating levels of ALP can be associated with a wide range of disease conditions [44, 45] , the abnormally high levels of ALP activities in the plasma and heart tissue of TO2 hamsters were detected in the absence of abnormal liver ALP activity. It should be mentioned that tissue calcification has been reported to be dependent on ALP activity [46] , and calcified lesions are commonly present in cardiomyopathic animals and patients [19, 46, 47] . Thus, cardiovascular calcification may be secondary to early presymptomatic activation of ALP. It is tempting to speculate that abnormally active Wnt/ b-catenin signaling may have a role in the early myocardial osteogenic phenotype since the signaling pathway is known to promote osteogenesis of mesenchymal tissue [48] , and appears to be more active in the TO2 myocardium [49] .
Understanding of cardiac metabolism can provide a new approach to the treatment of heart failure. Abnormalities in energetics are now considered an integral part of the primary heart muscle disease. Compromise of myocardial energy production pathways is thus expected to have a causal role in cardiomyopathies [50, 51] . The UM-X7.1 cardiomyopathic hamster strain has previously been found to exhibit insulin deficiency and reduced expression of lipogenic enzymes [32] . Although the cause of insulin dysfunction in the UM-X7.1 and TO2 strains remains unclear, it may be associated with additional mutation in these animals [52] . The present study shows that compromised glucose oxidative metabolism in the TO2 heart is caused by reduced expression and activity of the E1 subunit of PDH, which may be mediated by transient low insulin levels in TO2 hamsters. This altered PDH control in hamster DCM was also recognized previously [53] . Along this line, we note that GLUT4 knockout mice were found to exhibit depressed systolic function and eventually progress to DCM [54] . These findings suggest a potentially common myocardial maladaptation process involving glucose metabolism during the development of DCM, ultimately leading to ventricular pump failure. Notably, PDH deficiency in the TO2 heart was not detected at 1 month during which time ALP elevation and lipid peroxidation were already precipitated, suggesting that it likely contributes to the progression rather than initiation of hamster DCM.
In summary, the present study delineates an early pathogenic role of oxidative stress and osteogenic phenotype at the presymptomatic stage of d-sarcoglycan-null DCM. The symptomatic phase is marked by reduced expression and activity of PDH E1 subunit, which is expected to impair aerobic glucose metabolism. Differential involvement of oxidative stress, osteogenic phenotype, and glucose metabolism identify important dynamic venues, which may be therapeutically targeted for early diagnosis, prevention, and treatment of human DCM.
